secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2024-06-21T23:59:59+00:00
Accession:  0000950170-24-075880
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acasti Pharma FY2024 net loss $12.9M; STRIVE-ON trial on track for NDA in H1 2025
--------------------------------------------------------------------------------

- FY2024 net loss $12.9M ($1.35 per share), down from $42.4M in FY2023; decrease due to prior year impairments not recurring and restructuring.
- R&D expenses fell to $4.7M from $10.0M; G&A expenses down to $6.4M from $7.6M reflecting strategic realignment toward GTX-104.
- Cash and equivalents $23.0M as of March 31, 2024; projected runway into Q2 2026.
- STRIVE-ON Phase 3 safety trial enrollment on track; potential NDA submission to FDA in first half of 2025.
- Completed $7.5M private placement in September 2023; deprioritized GTX-102 and GTX-101 to focus on GTX-104.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000095017024075880/0000950170-24-075880-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000095017024075880/acst-20240621.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-075880

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer